[Form 3] XBiotech Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Thomas Martin Kuendig, a director of XBiotech Inc. (XBIT), filed an initial Form 3 disclosing beneficial ownership of 300,000 shares of the issuer's common stock. The filing reports 200,000 shares held directly and two indirect holdings of 50,000 shares each attributed to his daughters, Stephanie Kuendig and Michelle Kuendig. The event requiring the statement is dated 08/29/2025 and the form is signed on 09/29/2025. No derivative securities are reported on this form.

Positive

• Full disclosure of a director's equity position totaling 300,000 shares, with clear direct and indirect attribution
• No derivative securities reported, reducing immediate complexity about potential dilution

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine insider filing; director reports 300,000 total shares, split between direct and family-held indirect holdings.

The Form 3 is a standard initial disclosure that notifies the market of a director's equity stake. The total position of 300,000 common shares is disclosed with clear separation between 200,000 direct and 50,000+50,000 indirect family holdings. There are no reported derivative positions, which simplifies assessment of potential future dilution or option exercise impact. For most investors this is informational and not a material corporate event.

Corporate Governance Expert

TL;DR: Compliance-focused filing showing required Section 16 disclosure for a director; no red flags in reported holdings.

The filing satisfies Section 16 initial reporting obligations by identifying the reporter, relationship as a director, transaction date 08/29/2025, and the signature date 09/29/2025. Indirect holdings are properly attributed to immediate family members, which is standard practice. Absence of amendments or derivative reporting indicates a straightforward equity position. This is a routine governance disclosure rather than a corporate governance concern.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kuendig Thomas Martin

(Last) (First) (Middle)

ALPENSTRASSE 23

8803 RUESCHLIKON, KANTON OF ZUERICH

(Street)

RUESCHLIKON V8 8803

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/29/2025

3. Issuer Name and Ticker or Trading Symbol
XBiotech Inc. [ XBIT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	200,000	D
Common Stock	50,000	I	By Daughter #1 - Stephanie Kuendig
Common Stock	50,000	I	By Daughter #2 - Michelle Kuendig

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Thomas Kuendig	09/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Thomas Kuendig report on the Form 3 for XBiotech (XBIT)?

He reported beneficial ownership of 300,000 common shares: 200,000 direct and 50,000 each indirect via daughters Stephanie and Michelle Kuendig.

When is the date of the event and filing signature on the Form 3?

The event requiring the statement is dated 08/29/2025, and the Form 3 is signed on 09/29/2025.

Does the Form 3 for XBiotech (XBIT) report any options or derivative securities?

No. The filing shows no derivative securities in Table II.

What is Thomas Kuendig’s relationship to XBiotech listed on the form?

He is listed as a Director of XBiotech Inc.

Are the indirect holdings explained in the Form 3?

Yes. Indirect holdings are attributed to his daughters: Stephanie Kuendig (50,000) and Michelle Kuendig (50,000).